Susquehanna International Group, LLP Adaptimmune Therapeutics PLC Transaction History
Susquehanna International Group, LLP
- $688 Billion
- Q2 2025
A detailed history of Susquehanna International Group, LLP transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Susquehanna International Group, LLP holds 41,785 shares of ADAP stock, worth $6,267. This represents 0.0% of its overall portfolio holdings.
Number of Shares
41,785
Previous 17,344
140.92%
Holding current value
$6,267
Previous $3,000
233.33%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding ADAP
# of Institutions
68Shares Held
116MCall Options Held
10.3KPut Options Held
0-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$4.11 Million0.57% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR23.8MShares$3.56 Million0.26% of portfolio
-
Two Seas Capital LP Rye, NY22.6MShares$3.39 Million0.1% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$2.56 Million0.34% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.81MShares$721,4512.66% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $24.5M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...